Acarizax approved in Canada for young children

Following swiftly after US regulatory clearance for the same indication for Odactra tablet brand, Danish allergy expert ALK Abello (OMX: DC) its Acarizax announced that Health Canada has approved tablet for use in children, aged five to 11, with house dust mite (HDM) allergy.
Acarizax is now indicated for treatment of moderate to severe HDM-induced allergic rhinitis, with or without conjunctivitis, in children, adolescents, and adults in Canada aged five to 65.

Outside Europe, Canada is one of the most important markets for ALK’s respiratory tablet portfolio with sales growing continuously by double digits. Acarizax The expanded Acarizax label is expected to further benefit market uptake in Canada.

ALK executive vice president of R&D, Dr Henriette Mersebach, said: “Children suffering from uncontrolled respiratory allergic rhinitis are impacted socially and in school, and they may face severe health implications. We look forward to providing this treatment option and helping more children in Canada live better lives.”